Search - tctmd.com

Displaying 561 - 580 of 3027

Sort: Relevancy | Date

News Daily News

Anatomic Disease After PCI Linked With Worse Outcomes: VA CART

Michael O'Riordan

December 22, 2022

News Daily News

CVD Claimed 20 Million Lives in 2021, but Disease Burden Varies Globally

Michael O'Riordan

December 14, 2022

News Daily News

Shifting Acute MI Outcomes by Medicare Type: A Window Into Insurer’s Influence

L.A. McKeown

December 09, 2022

News Daily News

FFR Pullback Measure Linked to Likelihood of Angina Relief After PCI

Todd Neale

December 02, 2022

News Daily News

A Simple Nudge Moves the Needle on Statin Prescribing

Michael O'Riordan

December 02, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2022

Caitlin E. Cox

December 01, 2022

News Daily News

Nuisance Bleeds on DAPT Not Just an Annoyance: TALOS-AMI Analysis

Caitlin E. Cox

November 30, 2022

News Daily News

Think Before You Shake: UK Biobank Data Link Added Salt to Long-term CVD Risks

L.A. McKeown

November 30, 2022

News Daily News

P2Y12 Inhibitors Top Aspirin Following Post-PCI DAPT: Network Meta-analysis

Todd Neale

November 21, 2022

News Daily News

Single-Center Study Offers Insights for Ticagrelor vs Prasugrel in Chronic CAD

Yael L. Maxwell

November 21, 2022

News Daily News

Exposure to Lead Linked to Risk of CVD Mortality: Strong Heart Study

Michael O'Riordan

November 18, 2022

News Daily News

How Lp(a) Levels Compare With LDL-C in FH: Some Surprises

Michael O'Riordan

November 17, 2022

News Daily News

New Risk Models Superior to Pretest Probability at Predicting CAD

Yael L. Maxwell

November 15, 2022

News Daily News

Many STEMI Patients Not Treated Within National Time Goals

Michael O'Riordan

November 15, 2022

News Conference News AHA 2022

Cangrelor After Ticagrelor Pretreatment in ACS Might Be OK: SWAP-5

Yael L. Maxwell

November 11, 2022

News Conference News AHA 2022

Chinese Medicine Tongxinluo Yields ‘Surprising’ Benefits Post-STEMI: CTS-AMI

Shelley Wood

November 10, 2022

News Conference News AHA 2022

RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl

Todd Neale

November 10, 2022

News Conference News AHA 2022

Another OPTION? Indobufen Noninferior to Aspirin Following Successful PCI

Yael L. Maxwell

November 10, 2022

Presentation AHA 2022

Reduction of Lipoprotein(a) With Small Interfering RNA: Results of the OCEAN(a)-DOSE (TIMI 67) Trial

Presenter: Michelle L. O’Donoghue

November 07, 2022

Presentation AHA 2022

Bivalirudin Plus a High-dose Infusion Versus Heparin Monotherapy in Patients with STEMI Undergoing Primary PCI: The BRIGHT-4 Trial

Presenter: Gregg W. Stone

November 07, 2022

Advertisement

Anatomic Disease After PCI Linked With Worse Outcomes: VA CART

CVD Claimed 20 Million Lives in 2021, but Disease Burden Varies Globally

Shifting Acute MI Outcomes by Medicare Type: A Window Into Insurer’s Influence

FFR Pullback Measure Linked to Likelihood of Angina Relief After PCI

A Simple Nudge Moves the Needle on Statin Prescribing

TCTMD’s Top 10 Most Popular Stories for November 2022

Nuisance Bleeds on DAPT Not Just an Annoyance: TALOS-AMI Analysis

Think Before You Shake: UK Biobank Data Link Added Salt to Long-term CVD Risks

P2Y12 Inhibitors Top Aspirin Following Post-PCI DAPT: Network Meta-analysis

Single-Center Study Offers Insights for Ticagrelor vs Prasugrel in Chronic CAD

Exposure to Lead Linked to Risk of CVD Mortality: Strong Heart Study

How Lp(a) Levels Compare With LDL-C in FH: Some Surprises

New Risk Models Superior to Pretest Probability at Predicting CAD

Many STEMI Patients Not Treated Within National Time Goals

Cangrelor After Ticagrelor Pretreatment in ACS Might Be OK: SWAP-5

Chinese Medicine Tongxinluo Yields ‘Surprising’ Benefits Post-STEMI: CTS-AMI

RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl

Another OPTION? Indobufen Noninferior to Aspirin Following Successful PCI

Reduction of Lipoprotein(a) With Small Interfering RNA: Results of the OCEAN(a)-DOSE (TIMI 67) Trial

Bivalirudin Plus a High-dose Infusion Versus Heparin Monotherapy in Patients with STEMI Undergoing Primary PCI: The BRIGHT-4 Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content